Bioactive peptides against angiotensin‐converting enzyme I: An <scp><i>in silico</i></scp> study

Abstract Bioactive peptides are currently emerging as nonpharmacological alternatives for treating noncommunicable diseases, including hypertension. Pharmacological treatments hypertension typically involve angiotensin I converting enzyme inhibitors such Captopril and enalapril. This study aimed to evaluate the activity of bioactive derived from food sources against this show its possible mechanism inhibitory action. A comprehensive search was conducted in peptide databases identify with antihypertensive properties. Subsequently, docking studies, simulations, predictive tests assessing ADME parameters, intestinal stability, allergenicity were performed using bioinformatics tools. The simulation results demonstrated that PEP2 exhibited superior ACE1 potential compared other peptides, even though it had lower human absorption. In conclusion, suggests these hold promising nutraceuticals treatment.